Identification of novel prognostic biomarkers in diffuse large B cell lymphoma in the rituximab era
Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma and is characterized by marked clinical and genetic heterogeneity. Approximately 60% of patients with DLBCL are cured with multi-agent chemotherapy consisting of rituximab, cyclophosphamide, hydroxyldaunomycin, oncovin and pr...
| Main Author: | |
|---|---|
| Language: | English |
| Published: |
University of British Columbia
2010
|
| Online Access: | http://hdl.handle.net/2429/28126 |